Download Sample
Add to CartGlobal Intra-Abdominal Infection Treatment Market Growth, Share, Size, Trends and Forecast (2024 - 2030)
By Drugs;
Antibiotics, Anti-bacterials, Antifungals, Analgesics and Others.By Pathogens;
Gram-positive, Staphylococcus, Enterococcus, Streptococcus, Gram-negative, Bacteroides, Clostridium, Proteus, Klebsiella, Pseudomonas, Enterobacter, coli and Others.By Infection Type;
Community-acquired and Healthcare Associated.By Distribution Channel;
Institutional Pharmacies, Retail Pharmacies and Online Pharmacies.By End Users;
Hospitals, Clinics and Home Settings.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2020 - 2030).Introduction
Global Intra-Abdominal Infection Treatment Market (USD Million), 2020 - 2030
In the year 2023, the Global Intra-Abdominal Infection Treatment Market was valued at USD 802.89 million. The size of this market is expected to increase to USD 1129.75 million by the year 2030, while growing at a Compounded Annual Growth Rate (CAGR) of 5.0%.
The global intra-abdominal infection treatment market is a dynamic and rapidly evolving sector within the broader healthcare industry. Intra-abdominal infections (IAIs) represent a significant medical challenge worldwide, encompassing a range of conditions such as peritonitis, appendicitis, diverticulitis, and abscesses, among others. These infections can arise from various sources, including perforation of the gastrointestinal tract, traumatic injuries, postoperative complications, or underlying medical conditions.
In recent years, there has been a growing recognition of the complexity and severity of intra-abdominal infections, driving increased research and development efforts aimed at improving treatment options. Key factors contributing to the expansion of the intra-abdominal infection treatment market include rising incidence rates of IAIs, the emergence of antibiotic-resistant pathogens, advances in diagnostic techniques, and the development of innovative therapeutics.
The treatment landscape for intra-abdominal infections is multifaceted, typically involving a combination of surgical intervention and antimicrobial therapy. Surgical procedures may range from minimally invasive techniques, such as laparoscopy, to open abdominal exploration, depending on the severity and underlying cause of the infection. Meanwhile, antimicrobial therapy plays a crucial role in controlling the spread of infection and reducing morbidity and mortality rates.
Antibiotics remain the cornerstone of intra-abdominal infection treatment, with a variety of agents available for both empirical and targeted therapy. However, the rise of antimicrobial resistance poses a significant challenge to effective treatment, necessitating the development of novel antibiotics and alternative treatment strategies. Additionally, adjunctive therapies, such as probiotics, immunomodulators, and therapeutic agents targeting virulence factors, are under investigation for their potential to enhance treatment outcomes and reduce the burden of intra-abdominal infections.
The global intra-abdominal infection treatment market is characterized by intense competition among pharmaceutical companies, medical device manufacturers, and healthcare providers. Market players are actively engaged in product innovation, strategic collaborations, and mergers and acquisitions to strengthen their market position and address unmet medical needs. Moreover, increasing awareness of the importance of early diagnosis and prompt intervention is driving efforts to improve healthcare infrastructure and access to quality care, particularly in underserved regions.
Overall, the intra-abdominal infection treatment market is poised for continued growth in the coming years, fueled by ongoing advancements in medical technology, rising healthcare expenditure, and the increasing prevalence of intra-abdominal infections worldwide. However, significant challenges remain, including the threat of antimicrobial resistance, regulatory hurdles, and healthcare disparities, underscoring the need for collaborative efforts across the healthcare ecosystem to optimize patient outcomes and mitigate the impact of intra-abdominal infections.
Global Intra-Abdominal Infection Treatment Market Recent Developments & Report Snapshot
Recent Developments :
-
In May 2018, This guidance aimed to assist sponsors in developing drugs for treating complicated intra-abdominal infections (cIAIs), outlining the Food and Drug Administration’s (FDA’s) perspective on development programs and clinical trial designs to support a treatment indication for cIAI.
-
In March 2024, Pfizer Inc. announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had issued a positive opinion, recommending marketing authorization for EMBLAVEO to treat cIAI, HAP, VAP, and cUTI in adults with limited treatment options.
| Parameters | Description |
|---|---|
| Market | Global Intra-Abdominal Infection Treatment Market |
| Study Period | 2020 - 2030 |
| Base Year (for Intra-Abdominal Infection Treatment Market Size Estimates) | 2023 |
| Drivers |
|
| Restraints |
|
| Opportunities |
|
Segment Analysis
One significant segmentation is based on the type of infection being treated. Intra-abdominal infections can arise from various sources such as appendicitis, diverticulitis, cholecystitis, and peritonitis. Each type of infection may require a different approach to treatment, depending on its severity and underlying causes. For example, uncomplicated appendicitis may be treated with antibiotics alone, while complicated cases may require surgical intervention.
Another crucial segmentation is based on the treatment method. Intra-abdominal infections can be treated through both medical and surgical approaches. Medical treatment typically involves the administration of antibiotics to eradicate the infection, while surgical treatment may be necessary to remove infected tissue or drain abscesses. The choice of treatment method depends on factors such as the patient's overall health, the severity of the infection, and the presence of complications.
Geographical segmentation is also essential in analyzing the intra-abdominal infection treatment market. The prevalence of intra-abdominal infections and the availability of healthcare resources can vary significantly from one region to another. Developed regions such as North America and Europe may have better access to advanced medical treatments and surgical interventions, leading to higher market demand. In contrast, developing regions may face challenges such as limited access to healthcare facilities and lower awareness of intra-abdominal infections, affecting market growth in those areas.
Overall, a comprehensive understanding of these segmentation factors is crucial for stakeholders in the intra-abdominal infection treatment market to identify growth opportunities, tailor their marketing strategies, and develop innovative solutions to address the diverse needs of patients worldwide.
Global Intra-Abdominal Infection Treatment Segment Analysis
In this report, the Global Intra-Abdominal Infection Treatment Market has been segmented by Drugs, Pathogens, Infection Type, Distribution Channel, End Users and Geography.
Global Intra-Abdominal Infection Treatment Market, Segmentation by Drugs
The Global Intra-Abdominal Infection Treatment Market has been segmented by Drugs into Antibiotics, Anti-bacterials, Antifungals, Analgesics and Others.
Antibiotics play a crucial role in intra-abdominal infection management by targeting bacterial pathogens responsible for the infection. They are designed to inhibit the growth or kill bacteria, thereby curbing the spread of the infection and promoting recovery. Anti-bacterials, another significant category, function similarly to antibiotics but may have a broader spectrum of activity, targeting various types of bacteria.
In addition to antimicrobial agents, antifungals are essential components of intra-abdominal infection treatment, particularly in cases where fungal pathogens are involved. These drugs work by targeting fungal cells, disrupting their growth and proliferation within the abdominal cavity.
Analgesics represent another important aspect of treatment, providing relief from the discomfort and pain associated with intra-abdominal infections. By alleviating symptoms, analgesics improve patient comfort and aid in the overall management of the condition.
Beyond these primary categories, other drugs may also be employed in the treatment of intra-abdominal infections, depending on factors such as the underlying cause, severity of the infection, and individual patient characteristics. This multifaceted approach underscores the complexity of managing intra-abdominal infections effectively and underscores the need for a comprehensive treatment strategy tailored to the specific needs of each patient.
Global Intra-Abdominal Infection Treatment Market, Segmentation by Pathogens
The Global Intra-Abdominal Infection Treatment Market has been segmented by Pathogens into Gram-positive, Staphylococcus, Enterococcus, Streptococcus, Gram-negative, Bacteroides, Clostridium, Proteus, Klebsiella, Pseudomonas, Enterobacter and Others.
Gram-positive bacteria constitute a significant portion of intra-abdominal infections, with pathogens such as Staphylococcus, Enterococcus, and Streptococcus being prominent. Staphylococcus aureus, in particular, is a leading cause of community-acquired and hospital-acquired intra-abdominal infections, necessitating targeted treatment strategies. Enterococcus species, including Enterococcus faecalis and Enterococcus faecium, are also frequently encountered, especially in cases of secondary infections following gastrointestinal procedures. Streptococcus species, though less common, can still contribute to intra-abdominal infections, particularly in immunocompromised individuals or those with underlying conditions.
Gram-negative bacteria represent another significant category of pathogens implicated in intra-abdominal infections. Among these, Bacteroides and Clostridium species are noteworthy for their ability to thrive in the anaerobic environment of the abdomen. Bacteroides fragilis, in particular, is a leading anaerobic pathogen responsible for intra-abdominal abscesses and peritonitis. Clostridium difficile, though primarily associated with antibiotic-associated diarrhea, can also cause severe intra-abdominal infections, highlighting the importance of targeted antimicrobial therapy.
Gram-negative bacilli such as Proteus, Klebsiella, Pseudomonas, and Enterobacter species are common culprits in intra-abdominal infections, especially in healthcare settings. These organisms possess various virulence factors and mechanisms of antibiotic resistance, posing challenges for treatment and management. Proteus mirabilis and Klebsiella pneumoniae, for instance, are notorious for their ability to form biofilms and cause persistent infections. Pseudomonas aeruginosa, with its intrinsic resistance mechanisms and ability to thrive in diverse environments, presents a formidable adversary in intra-abdominal infections. Enterobacter species, including E. coli, are also prevalent causes of intra-abdominal infections, with multidrug-resistant strains posing a growing threat worldwide.
The "Others" category encompasses less common pathogens or emerging infectious agents that may contribute to intra-abdominal infections. This may include atypical organisms, opportunistic pathogens, or newly recognized species with pathogenic potential. Given the dynamic nature of microbial ecology and the ongoing evolution of antimicrobial resistance, continual surveillance and research are essential to stay ahead of emerging threats in the Global Intra-Abdominal Infection Treatment Market. Effective management of intra-abdominal infections requires a multifaceted approach, encompassing antimicrobial therapy, surgical intervention, and supportive care, tailored to the specific pathogens involved and the clinical context of each case.
Global Intra-Abdominal Infection Treatment Market, Segmentation by Infection Type
The Global Intra-Abdominal Infection Treatment Market has been segmented by Infection Type into Community-acquired and Healthcare associated.
Community-acquired intra-abdominal infections refer to infections that originate outside of healthcare facilities, typically occurring in individuals who have not recently been hospitalized or undergone surgical procedures. These infections can result from a variety of sources, including perforated appendicitis, diverticulitis, or traumatic injuries to the abdomen. The treatment approach for community-acquired infections often involves a combination of antibiotics, surgical drainage or debridement, and supportive care.
Healthcare-associated intra-abdominal infections occur in patients who have been hospitalized or undergone surgical procedures within a healthcare setting. These infections are often associated with invasive medical interventions, such as abdominal surgery, endoscopic procedures, or the placement of medical devices like catheters or feeding tubes. Healthcare-associated infections can be more challenging to treat due to factors such as antibiotic resistance and the presence of multidrug-resistant organisms in hospital settings. Treatment typically involves a combination of broad-spectrum antibiotics, surgical intervention, and intensive supportive care.
Overall, the treatment landscape for intra-abdominal infections continues to evolve with advancements in antimicrobial therapy, surgical techniques, and infection prevention strategies. Healthcare providers must remain vigilant in their approach to diagnosing and managing these infections to minimize complications and improve patient outcomes in both community and healthcare settings.
Global Intra-Abdominal Infection Treatment Market, Segmentation by Distribution Channel
The Global Intra-Abdominal Infection Treatment Market has been segmented by Distribution Channel into Institutional Pharmacies, Retail Pharmacies and Online Pharmacies.
Institutional pharmacies, often located within hospitals or healthcare institutions, are integral in the distribution of intra-abdominal infection treatments. These pharmacies cater primarily to inpatients and outpatients receiving care within the institution. They offer the advantage of immediate access to medications prescribed by healthcare providers, ensuring timely initiation of treatment. Additionally, institutional pharmacies often stock a wide range of medications, including specialized antibiotics and intravenous formulations, tailored to the needs of critically ill patients requiring intensive care.
Retail pharmacies, found in community settings such as standalone stores or within larger retail chains, are another essential distribution channel for intra-abdominal infection treatments. These pharmacies serve a broad patient population, including individuals discharged from hospitals, outpatients, and those managing chronic conditions at home. Retail pharmacies provide convenience and accessibility, allowing patients to fill prescriptions and obtain necessary medications close to their homes. Pharmacists in these settings may also offer counseling and support services, enhancing patient adherence to treatment regimens and promoting positive health outcomes.
The emergence of online pharmacies has transformed the distribution landscape for intra-abdominal infection treatments, offering an alternative to traditional brick-and-mortar pharmacies. Online pharmacies provide patients with the convenience of ordering medications from the comfort of their homes and receiving doorstep delivery. This distribution channel is particularly advantageous for individuals with limited mobility, those residing in remote areas, or those seeking privacy and discretion in obtaining medications. However, the proliferation of online pharmacies also raises concerns regarding the authenticity and quality of medications, highlighting the importance of regulatory oversight and adherence to safety standards.
In summary, the distribution channels of institutional pharmacies, retail pharmacies, and online pharmacies collectively contribute to ensuring the availability and accessibility of intra-abdominal infection treatments to patients worldwide. Each channel offers unique benefits and addresses specific needs within the healthcare ecosystem. As the landscape continues to evolve, stakeholders must collaborate to optimize these channels, enhance patient outcomes, and mitigate challenges associated with medication distribution.
Global Intra-Abdominal Infection Treatment Market, Segmentation by End Users
The Global Intra-Abdominal Infection Treatment Market has been segmented by End Users into Hospitals, Clinics and Home Settings.
Hospitals serve as primary hubs for managing severe cases, offering advanced medical facilities and specialized care. They often handle complex procedures and provide round-the-clock monitoring, making them crucial in the treatment of critical intra-abdominal infections.
Clinics, on the other hand, cater to a broader spectrum of patients, offering both primary and specialized care. They play a significant role in early diagnosis, routine check-ups, and less severe cases of intra-abdominal infections. Clinics provide a more accessible option for patients requiring regular monitoring or follow-up care.
The inclusion of home settings in the segmentation highlights the growing trend towards home healthcare and outpatient management of certain medical conditions. For less severe cases or patients in recovery stages, home settings offer comfort, convenience, and reduced risk of nosocomial infections. Home-based treatments may include medication administration, wound care, and remote monitoring, facilitated by healthcare professionals or caregivers.
By recognizing the diverse needs and preferences of patients, the segmentation of the intra-abdominal infection treatment market into hospitals, clinics, and home settings aims to optimize healthcare delivery and improve patient outcomes across various care settings.
Global Intra-Abdominal Infection Treatment Market, Segmentation by Geography
In this report, the Global Intra-Abdominal Infection Treatment Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Intra-Abdominal Infection Treatment Market Share (%), by Geographical Region, 2023
The Global Intra-Abdominal Infection Treatment Market is a vital sector within the broader healthcare landscape, addressing the urgent need for effective therapies to combat intra-abdominal infections, which pose significant health risks worldwide. Geographical segmentation is a crucial aspect of understanding the market dynamics, as it allows for targeted strategies tailored to the unique healthcare needs and infrastructures of different regions.
North America stands out as a prominent market segment for intra-abdominal infection treatment. The region boasts advanced healthcare infrastructure, robust regulatory frameworks, and high healthcare expenditure, which collectively contribute to the widespread adoption of innovative treatment options. Additionally, a high prevalence of intra-abdominal infections, coupled with increasing cases of antibiotic-resistant pathogens, drives the demand for novel therapeutic solutions in this region. Furthermore, the presence of key market players and research institutions focused on infectious diseases fuels the development and commercialization of new treatment modalities.
Europe represents another significant market segment for intra-abdominal infection treatment. Similar to North America, Europe benefits from well-established healthcare systems and a strong emphasis on research and development. The region is characterized by a growing elderly population, who are more susceptible to intra-abdominal infections, thereby driving the demand for effective treatment options. Moreover, initiatives to combat antimicrobial resistance and improve patient outcomes further stimulate market growth in Europe. Collaborative efforts between healthcare stakeholders, including governments, industry players, and healthcare providers, are instrumental in advancing the diagnosis and management of intra-abdominal infections across the continent.
Asia Pacific emerges as a rapidly expanding market segment for intra-abdominal infection treatment, fueled by factors such as population growth, urbanization, and increasing healthcare investments. Countries in this region exhibit a high burden of intra-abdominal infections, driven by factors such as inadequate sanitation, limited access to healthcare, and the prevalence of infectious diseases. As healthcare infrastructures continue to improve and awareness of intra-abdominal infections rises, there is a growing demand for innovative treatment options in Asia Pacific. Additionally, the presence of a large patient population and a rising incidence of healthcare-associated infections underscore the need for effective infection control measures and treatment strategies in this region.
Other regions, including Latin America, the Middle East, and Africa, also contribute to the global intra-abdominal infection treatment market. While these regions may face challenges such as healthcare infrastructure deficiencies and economic constraints, efforts to improve healthcare access and address infectious diseases drive market growth. Moreover, collaborations with international organizations and initiatives to strengthen healthcare systems enhance the availability of intra-abdominal infection treatment options in these regions.
In summary, geographical segmentation provides valuable insights into the diverse factors shaping the Global Intra-Abdominal Infection Treatment Market. By understanding regional differences in disease burden, healthcare infrastructure, and regulatory landscapes, stakeholders can develop tailored strategies to address unmet medical needs and drive innovation in intra-abdominal infection treatment worldwide.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Intra-Abdominal Infection Treatment Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers:
- Surgical intervention
- Minimally invasive techniques
- Antimicrobial therapy
-
Adjunctive therapies -In the global intra-abdominal infection treatment market, adjunctive therapies play a crucial role in enhancing patient outcomes and reducing the burden of infections. Adjunctive therapies refer to additional treatments used in conjunction with primary therapies, such as antibiotics or surgical intervention, to improve efficacy or address specific aspects of the infection. Several adjunctive therapies are utilized in the management of intra-abdominal infections:
In severe cases of intra-abdominal infection, patients may experience fluid loss due to factors such as vomiting, diarrhea, or sepsis. Fluid resuscitation with intravenous fluids helps restore blood volume and maintain vital organ perfusion, which is essential for stabilizing patients and supporting their recovery.
Intra-abdominal infections can cause significant pain and discomfort for patients. Effective pain management strategies, including analgesic medications and regional anesthesia techniques, can improve patient comfort, facilitate early mobilization, and support the recovery process.
Infections can increase metabolic demands and alter nutrient absorption, leading to malnutrition and impaired immune function. Nutritional support, such as enteral or parenteral nutrition, ensures adequate caloric intake and nutrient supplementation to support the body's immune response and promote tissue healing.
Emerging research suggests that probiotics and prebiotics may play a role in modulating the gut microbiota and reducing the risk of intra-abdominal infections, particularly in critically ill patients receiving antibiotics. These adjunctive therapies aim to restore microbial balance and prevent secondary infections, although further studies are needed to establish their efficacy definitively.
Intra-abdominal infections often require source control measures, such as drainage of abscesses or removal of necrotic tissue, to eliminate the source of infection and prevent disease progression. These adjunctive procedures may be performed concurrently with antibiotic therapy or surgical intervention to optimize treatment outcomes.
Immunomodulatory agents, such as cytokine inhibitors or immunostimulants, are under investigation as potential adjunctive therapies for intra-abdominal infections. These agents target the host immune response to modulate inflammation, enhance pathogen clearance, and promote tissue repair, although their clinical utility and safety profile require further evaluation.
Overall, adjunctive therapies play a critical role in the comprehensive management of intra-abdominal infections, addressing various aspects of patient care beyond antimicrobial or surgical interventions. By integrating adjunctive therapies into treatment protocols, healthcare providers can optimize outcomes, reduce complications, and improve the overall quality of care for patients with intra-abdominal infections.
Restraints:
- Antimicrobial resistance
- Limited treatment options
- High healthcare costs
-
Drug shortages -The Global Intra-Abdominal Infection Treatment Market has faced challenges due to drug shortages, impacting the availability and accessibility of essential medications for patients. These shortages can result from various factors, including manufacturing issues, supply chain disruptions, regulatory issues, and increased demand.
In the context of intra-abdominal infections, the shortage of key antibiotics and other drugs can significantly impact patient care and treatment outcomes. Antibiotics play a critical role in the management of intra-abdominal infections by targeting the underlying bacterial pathogens responsible for the infection. Shortages of these antibiotics can lead to delays in treatment initiation, inadequate dosing, or the need to switch to alternative medications that may be less effective or associated with higher risks of adverse effects.
The consequences of drug shortages extend beyond individual patient care and can have broader implications for healthcare systems and public health. Shortages may increase healthcare costs, strain healthcare resources, and contribute to the development of antimicrobial resistance. Moreover, they can compromise the ability of healthcare providers to effectively respond to infectious disease outbreaks or other public health emergencies.
Drug shortages in the Global Intra-Abdominal Infection Treatment Market requires a multifaceted approach involving collaboration among healthcare providers, pharmaceutical companies, regulators, policymakers, and other stakeholders. Strategies to mitigate drug shortages may include improving communication and transparency in the supply chain, implementing risk management plans to identify and address potential shortages proactively, investing in manufacturing capacity and infrastructure, and promoting the development of alternative treatment options.
By addressing the underlying causes of drug shortages and implementing proactive measures to ensure a stable and reliable supply of essential medications, stakeholders can help safeguard patient access to effective treatment and improve outcomes for individuals with intra-abdominal infections.
Opportunities:
- Antibiotic stewardship
- Novel antimicrobial agents
- Minimally invasive surgical techniques
-
Point-of-care diagnostics -In the Global Intra-Abdominal Infection Treatment Market, point-of-care diagnostics play a pivotal role in improving patient outcomes and optimizing treatment strategies. Point-of-care diagnostics refer to medical tests conducted at or near the site of patient care, providing rapid results that enable timely clinical decisions. These diagnostics are particularly valuable in the context of intra-abdominal infections, where early detection and targeted therapy are critical for successful outcomes.
Point-of-care diagnostics offer several advantages in the management of intra-abdominal infections. Firstly, they facilitate prompt identification of infectious agents, allowing healthcare providers to initiate appropriate antimicrobial therapy promptly. This rapid turnaround time is crucial in preventing disease progression and reducing the risk of complications associated with intra-abdominal infections, such as sepsis or organ dysfunction.
Point-of-care diagnostics enable healthcare providers to implement antimicrobial stewardship programs effectively. By identifying the causative pathogens and their susceptibility patterns in real-time, clinicians can tailor antibiotic therapy to the specific needs of individual patients, minimizing the risk of antibiotic resistance and adverse drug reactions. This targeted approach not only improves patient outcomes but also conserves valuable healthcare resources and reduces healthcare costs associated with unnecessary antibiotic use.
Point-of-care diagnostics enhance the efficiency of patient management in various healthcare settings, including hospitals, clinics, and emergency departments. These tests are designed to be user-friendly and require minimal training, enabling healthcare providers to perform rapid assessments at the bedside or in outpatient settings. As a result, patients receive timely interventions, leading to shorter hospital stays, reduced treatment delays, and improved overall satisfaction with healthcare services.
Point-of-care diagnostics facilitate decentralized healthcare delivery models, particularly in resource-limited settings and underserved communities. These tests can be deployed in remote areas or field clinics, where access to centralized laboratory facilities may be limited. By bringing diagnostic capabilities closer to the point of patient care, point-of-care diagnostics empower frontline healthcare workers to diagnose and manage intra-abdominal infections effectively, even in challenging environments.
In conclusion, point-of-care diagnostics represent a valuable tool in the Global Intra-Abdominal Infection Treatment Market, offering rapid and accurate diagnostic capabilities that enhance clinical decision-making and patient care. By enabling early detection, targeted therapy, and efficient resource utilization, point-of-care diagnostics contribute to improved outcomes for patients with intra-abdominal infections and support the broader goal of combating infectious diseases on a global scale.
Competitive Landscape Analysis
Key players in Global Intra-Abdominal Infection Treatment Market include.
- Mylan Pharmaceuticals Inc.
- Sun Pharmaceutical Industries
- Teva Pharmaceuticals USA
- Dr. Reddys Laboratories
- Merck & Co
- Roche Holding AG
- GlaxoSmithKline plc
- Pfizer Inc
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Drugs
- Market Snapshot, By Pathogens
- Market Snapshot, By Infection Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By End Users
- Market Snapshot, By Region
- Global Intra-Abdominal Infection Treatment Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
-
Surgical intervention
-
Minimally invasive techniques
-
Antimicrobial therapy
-
Adjunctive therapies
-
- Restraints
-
Antimicrobial resistance
-
Limited treatment options
-
High healthcare costs
-
Drug shortages
-
- Opportunities
-
Antibiotic stewardship
-
Novel antimicrobial agents
-
Minimally invasive surgical techniques
-
Point-of-care diagnostics
-
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Intra-Abdominal Infection Treatment Market, By Drugs, 2020-2030 (USD Million)
- Antibiotics
- Anti-bacterials
- Antifungals
- Analgesics
- Global Intra-Abdominal Infection Treatment Market, By Pathogens, 2020-2030 (USD Million)
- Gram-positive
- Staphylococcus
- Enterococcus
- Streptococcus
- Gram-negative
- Bacteroides
- Clostridium
- Proteus
- Klebsiella
- Pseudomonas
- Enterobacter
- coli
- Others
- Global Intra-Abdominal Infection Treatment Market, By Infection Type, 2020-2030 (USD Million)
- Community-acquired
- Healthcare Associated
- Global Intra-Abdominal Infection Treatment Market, By Distribution Channel, 2020-2030 (USD Million)
- Institutional Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Intra-Abdominal Infection Treatment Market, By End Users, 2020-2030 (USD Million)
- Hospitals
- Clinics
- Home Settings
- Global Intra-Abdominal Infection Treatment Market, By Geography, 2020-2030 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Intra-Abdominal Infection Treatment Market, By Drugs, 2020-2030 (USD Million)
- Competitive Landscape
- Company Profiles
- Mylan Pharmaceuticals Inc.
- Sun Pharmaceutical Industries
- Teva Pharmaceuticals USA
- Dr. Reddys Laboratories
- Merck & Co
- Roche Holding AG
- GlaxoSmithKline plc
- Pfizer Inc
- Company Profiles
- Analyst Views
- Future Outlook of the Market